Clinical benefit of subsequent chemotherapy after drug-induced interstitial lung disease in pancreatic cancer patients: a multicenter retrospective study from Japan
Authors:
- Hiroki IrieHIHiroki Irie
- Rei SuzukiRSRei Suzuki
- Yoshinori OkuboYOYoshinori Okubo
- Hiroyuki AsamaHAHiroyuki Asama
- Naoki KonnoNKNaoki Konno
- Yuki NoguchiYNYuki Noguchi
- Ko WatanabeKWKo Watanabe
- Goro ShibukawaGSGoro Shibukawa
- Hidemichi ImamuraHIHidemichi Imamura
- Tadayuki TakagiTTTadayuki Takagi
- Mitsuru SugimotoMSMitsuru Sugimoto
- Yuki SatoYSYuki Sato
Open Access
- 6 April 2023
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-6
Abstract
Purpose: Drug-induced interstitial lung disease (ILD) is not a rare adverse event in the current chemotherapy strategy for pancreatic ductal adenocarcinoma (PDAC). Thus, we aimed to find the optimal management for PDAC patients with a history of ILD induced by a gemcitabine-based regimen. Methods: We conducted a multicenter retrospective study. The primary endpoint was the overall survival (OS) of patients who underwent either S-1 monotherapy or FOLFOX after the onset of ILD. Toxicity data was also analyzed in the 2 groups. Results: Twenty-four patients were diagnosed with ILD and 17 patients who received subsequent chemotherapy were enrolled in the study. Among 17 patients who were managed with subsequent chemotherapy after recovering from ILD, we did not observe significant difference in OS between S-1 and FOLFOX (290.0 days vs. undefined, p = 0.39). Relapse of drug-induced ILD was not observed in all cases during the course. Overall, severe adverse events (CTCAE Grade 3 or 4) were observed in 3 patients (23.1%) in S-1 treatment group and 1 patient (25.0%) in FOLFOX treatment group (p = 0.93). Conclusions: S-1 monotherapy and FOLFOX are comparable as the subsequent chemotherapy after gemcitabine-based chemotherapy-induced ILD in unresectable PDAC.Keywords
Funding Information
- Japan Society for the Promotion of Science (20K16419)
This publication has 21 references indexed in Scilit:
- Five Cases of Interstitial Pneumonitis Due to Gemcitabine and Nab-Paclitaxel Combination Treatment in Pancreatic Cancer PatientsPancreas, 2018
- Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysisInvestigational New Drugs, 2018
- Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancerJournal of Gastrointestinal Oncology, 2017
- FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysisThe Lancet Oncology, 2016
- FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM studyBMC Cancer, 2014
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST StudyJournal of Clinical Oncology, 2013
- XELOX versus FOLFOX4 as Second Line Chemotherapy in Advanced Pancreatic CancerHepatogastroenterology, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancerBritish Journal of Cancer, 2009